In the wake of Hurricane Maria, J&J says the company's Puerto Rico manufacturing plants "fared well," but "intermittent" shortages…

Some generics makers are responding to industrywide pricing pressure by bulking up via M&A. Not Novartis.

After stirring up a tribal licensing controversy, Allergan has run into a patent setback with big-selling eye medication Restasis.

Investors are demanding change at top drug distributors after an investigation exposed lax controls and lots of Capitol Hill arm-twisting.

FDA reviewers flagged data on cardiovascular benefits—and potential eye risks—posed by Novo Nordisk's semaglutide, up for approval later this year.

Mylan and other generics makers urged a Texas judge to call Allergan's Restasis patent deal with the Saint Regis Mohawk Tribe a "sham."

Shire has hinted that a spinoff of its neuroscience unit may be in the works. But one U.S. hedge fund wants more.

Sugarpod, a voice-enabled diabetes plan that uses Amazon's Alexa to help people complete daily tasks by speaking, won Merck’s tech challenge.

J&J’s Stelara has plenty of new competition in the adult psoriasis market, so it’s gone where many of its rivals haven’t: the adolescent population.

When it comes to payer marketing, the people pharma want to reach are digital-savvy researchers who prefer to get info online, new research has found.